HeartBeam (BEAT)
NASDAQ:BEAT
Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$47.29M
Enterprise Value$25.99M
Total Cash (Recent Filing)$4.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 13, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding53,631,836
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$4.38Price Target Upside70.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$2.08M
Bulls Say, Bears Say
Bulls Say
Regulatory ClearancesTwo FDA 510(k) clearances materially de-risk the core technology and ease commercial adoption by clinicians. Demonstrated productive FDA engagement (overturned an NSE quickly) shortens regulatory cycles for related features and strengthens the company’s ability to scale sales into regulated care settings.
12‑lead Patch PrototypeA functioning extended‑wear 12‑lead patch that combines continuous single‑lead monitoring with instant 12‑lead capture represents a durable product moat versus single‑lead patches. Clinical programs supporting the patch can validate superiority, enable recurring revenue models, and broaden addressable market beyond niche concierge accounts.
Completed Equity FinancingThe April 2026 underwritten offering meaningfully replenishes capital to execute commercialization, advance the patch and ACS programs, and fund AI development. This financing extends runway, reduces immediate solvency risk, and increases probability the company can complete pilots and pivotal work without imminent emergency funding.
Bears Say
No Revenue; Ongoing LossesThe company reports no revenue with large, persistent net losses and negative free cash flow, indicating operations are not yet self‑sustaining. Long‑term viability depends on successful commercialization and reimbursement; continued reliance on financing risks dilution and constrains strategic flexibility if market uptake lags.
Insufficient Cash RunwayA sizable gap between cash on hand and planned 2026 operating outflows creates a structural execution risk: pivotal trials, commercialization and hiring could be delayed if additional capital terms are unfavorable. Dependence on markets/ATMs makes long‑range planning and partner negotiations more uncertain.
ACS Regulatory Pathway UncertaintyUnclear regulatory route for the ACS/ischemia indication means longer timelines, potential need for de novo submission and a costly pivotal study. This structural uncertainty raises program costs, delays market access and reimbursement, and could push out broader commercial rollouts tied to the ACS claim.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $47.29M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is May 13, 2026 which is in 9 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Mar 12, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.14.
How many shares outstanding does HeartBeam have?
HeartBeam has 53,631,836 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -7.483%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.38 (70.90% Upside)
$4.38 (70.90% Upside)
Insider Transactions
Bought Shares
Worth $905.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-571.06%
Trailing 12-Months
Asset Growth
78.36%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful de‑risking of the underlying technology (two FDA 510(k) clearances, working patch prototype, ALIGN ACS pilot enrollment, AI collaboration with Mount Sinai, and an initial commercial partner) and a disciplined cost posture. However, these operational and clinical achievements are balanced by material near‑term financial risk (only $4.4M cash on hand vs. projected $17M–$19M burn in 2026), uncertain regulatory pathway for the ACS indication, and the need to validate commercial adoption beyond a small concierge initial market. Overall, the company demonstrated strong technical and strategic progress but faces significant execution and funding risks that temper the outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$4.38
▲(70.90% Upside)
Technical Analysis
Ownership Overview
10.84% Insiders
2.19% Mutual Funds
1.14% Other Institutional Investors
83.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---